Ticker: TSX - TOS
Shares Outstanding: 46,232,102
QUEBEC, April 26 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS) announce
today that it will host its fiscal 2006 Annual Shareholders Meeting on
Thursday, May 3, 2007. The Meeting will be held at the McCord Museum of
Canadian History, J. Armand Bombardier Theatre, 690 Sherbrooke Street West,
Montréal at 10:30 A.M. (ET). For those who are unable to attend in person, a
webcast of the meeting and management presentation will be available on the
TSO3's website at www.tso3.com.
TSO3 is located in Québec City, Québec, Canada, and was founded in 1998.
The Company's mission is to develop and market innovative and comprehensive
sterilization solutions. TSO3 has perfected an innovative sterilization
process using ozone as the sterilizing agent. The first product based on this
technological platform is the 125L Ozone Sterilizer, which is intended for
hospital sterilization units. The 125L - named after its
125- litre/4.3-cubic-foot capacity - was designed to sterilize heat-sensitive
surgical and diagnostic devices which are expensive and in high demand from
the surgical suite. The ozone sterilization process is a safe, efficacious,
fast and cost-effective response to evolving sterilization needs.
The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization
by Health Canada and by the U.S. Food and Drug Administration (FDA). On
August 3, 2006, the FDA authorized the utilization of the 125L Ozone
Sterilizer for sterilizing a significantly broader range of lumened
instruments that are longer and with smaller interior diameters.
TSO3 currently has more than 60 employees, 23 of whom work in the sales
and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Mathieu Claise, Interim Director, Corporate
Communications and Investor Relations, (418) 651-0003, Ext. 237, email@example.com;
Source: TSO3 Inc